Patent · US Active

Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A

US8062907B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Norbert Wild · Geretsried, DE
Veit Peter Grunert · Munich, DE
Johann Karl · Peißenberg, DE
Werner Zolg · Weilheim in Oberbayern, DE

Key dates

Filing date	Feb 10, 2011
Grant date	Nov 22, 2011
Priority date	—
Expiry date	Feb 10, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method for assessing a severity of rheumatoid arthritis. The method involves measuring in a patient sample a concentration of anti-cyclic citrullinated peptides (anti-CCP) and serum amyloid A, combining the concentrations determined to obtain a combined value, and comparing the combined value to a cut-off value established from a reference population. In another method, a marker selected from the group consisting of C-reactive protein (CRP), interleukin 6 (IL-6), S100 protein, osteopontin, rheumatoid factor (RF), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, and soluble CD14 (sCD14) may also be determined along with the anti-CCP and serum amyloid A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.